Paper Details

  1. Home
  2. Paper Details

Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.

Author: BarnettAnthony H, CharbonnelBernard, KalraSanjay, MosesRobert G

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Triple oral therapy is an option for patients with type 2 diabetes mellitus (T2DM) inadequately controlled by dual combination therapy. Agents should have complementary mechanisms of action and minimal risk of added side effects. This review discusses considerations for selecting triple oral therapy regimens and reviews clinical trial data on triple oral therapy using dipeptidyl peptidase-4 (DPP-4) inhibitors.
Paper Details　
Original Abstract of the Article :
There is no clear consensus regarding treatment of patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. Recommended agents for triple combination therapy should have complementary mechanisms of action with minimal risk of added side effects su...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007995.2015.1081589

データ提供：米国国立医学図書館（NLM）

Triple Therapy for Type 2 Diabetes: DPP-4 Inhibitors in Focus

The management of type 2 diabetes mellitus (T2DM) often involves a combination of medications to effectively control blood sugar levels. This review examines the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in triple oral therapy regimens for patients with T2DM whose condition is not adequately controlled with dual combination therapy. The authors analyze the available clinical trial data on DPP-4 inhibitors, providing insights into their effectiveness and safety when used in triple therapy combinations.

Balancing Effectiveness and Safety in Diabetes Treatment

The review highlights the importance of selecting triple therapy combinations that have complementary mechanisms of action while minimizing the risk of adverse side effects like weight gain and hypoglycemia. DPP-4 inhibitors are presented as a promising addition to triple therapy regimens, as they have demonstrated effectiveness in improving glycemic control without significant adverse effects. The review also explores the specific considerations for selecting triple oral therapy combinations based on individual patient characteristics and clinical needs.

Navigating the Complexities of Diabetes Management

Imagine a vast desert, where the oasis represents optimal glycemic control for individuals with T2DM. Navigating this desert, however, requires careful consideration of the various treatment options available. This review sheds light on the role of DPP-4 inhibitors in triple therapy combinations, providing clinicians with valuable insights for guiding their treatment decisions. The goal is to find the most effective and safe combination for each patient, ensuring they can reach the oasis of optimal health.

Dr.Camel's Conclusion

Diabetes management is a journey through a complex desert, requiring careful navigation and the right tools. This review offers valuable insights into the role of DPP-4 inhibitors in triple therapy combinations, providing clinicians with the guidance they need to create personalized treatment plans. By understanding the strengths and limitations of different treatment options, we can work towards a healthier future for individuals living with T2DM.

Date :
  1. Date Completed 2016-05-19
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26361231

DOI: Digital Object Identifier

10.1185/03007995.2015.1081589

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.